Reasons for trial discontinuation a | Neoplasms(n = 77) | Non-neoplasms (n = 235) | P |
---|---|---|---|
Drug development strategy | |||
 Commercial or strategic decision b | 13 (16.9) | 71 (30.2) | 0.022c |
 Lack of funding | 1 (1.3) | 6 (2.6) | 1.000d |
 Trial exemption | 1 (1.3) | 6 (2.6) | 1.000d |
Trial planning | |||
 Protocol issues b | 10 (13.0) | 31(13.2) | 0.963c |
 Poor recruitment b | 16 (20.8) | 19 (8.1) | 0.002c |
 Inadequate supplies | 0 (0) | 9 (3.8) | 0.119d |
 Study centre availability | 0 (0) | 11 (4.7) | 0.072d |
 Experimental conditions failed to meet requirements | 1 (1.3) | 3 (1.3) | 1.000d |
Trial conduct | |||
 Good laboratory or clinical practice | 1 (1.3) | 9 (3.8) | 0.460d |
 Poor compliance of volunteers | 0 (0) | 2 (0.9) | 1.000d |
 Insufficient preparation | 2 (2.6) | 9 (3.8) | 1.000d |
 Poor management ability of the principal investigator | 0 (0) | 2 (0.9) | 1.000d |
Studied drug | |||
 Futility/lack of efficacy b | 22 (28.6) | 48 (20.4) | 0.137c |
 Safety | 9 (11.7) | 12 (5.1) | 0.045c |